42 results about "Hla class ii" patented technology

Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.

The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

The invention discloses a preparation method and application of a sepsis-related encephalopathy model based on HLA II type gene humanized mice. According to the invention, HLA DP401 / DRA-IA beta- / -transgenic humanized mice are utilized, and the HLAII type gene humanized mouse sepsis model is prepared through mouse cecum seroperitoneal infection (CS) and meropenem intervention. The sepsis encephalopathy model can be comprehensively evaluated through indexes such as clinical score MSS, serum and hippocampal tissue inflammatory cytokine detection, hippocampal tissue microglial cell activation, hippocampal neuron spinous process change, transcriptomics, behavioral change and the like, and the sepsis encephalopathy model can be used for screening therapeutic drugs and therapeutic schedules; the HLA II type gene humanized mouse sepsis-related encephalopathy model provided by the invention can be used for infectious encephalopathy pathogenesis research, new drug research and development and safety evaluation.

The present invention relates to the technical field of biology, and particularly relates to a method for inhibiting an inflammatory response by using a fibroblast. In the present invention, a fibroblast, which is obtained by digesting normal foreskin tissue by means of clostridiopeptidase A to isolate a cell as a seed cell and culturing the seed cell in vitro by using a serum-free medium, shows positive expression of CD105, CD90, CD73, COL1A1, and FAP, with expression rates all exceeding 80%, and negative expression of CD36, CD39, CD45, and HLA class II molecules, with expression rates below 5%. The fibroblast can regulate an immune response by secreting TGFβ, inhibiting proliferation of PBMCs, thereby inhibiting the inflammatory response, and has been verified in an animal experiment to have the ability to repair knee osteoarthritis caused by meniscus injury. Therefore, the fibroblast can be used for preventing and treating inflammatory lesions such as osteoarthritis.

In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof to provide immune compatible, allogeneic cell therapies. In the various aspects and embodiments, the cell populations and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the populations by gene editing, and methods for cell therapy involving cells or tissues derived from the cell populations (including but not limited to hematopoietic stem cells, or "HSCs", progenitors, or progenies thereof).

The present disclosure relates to HLA class II molecules having higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecules comprise a DQ beta chain having: (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, or (iii) both (i) and (ii). Certain aspects of the present disclosure relate to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecules, cells comprising them, and methods of using the same.

The present disclosure relates to HLA class II molecules having higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecules comprise a DR beta chain having: (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure relate to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecules, cells comprising them, and methods of using the same.

The present disclosure relates to HLA class II molecules having higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecules comprise a DP beta chain having: (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, or (iii) both (i) and (ii). Certain aspects of the present disclosure relate to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecules, cells comprising them, and methods of using the same.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention relates to a safe and feasible triple strategy based on i) a gene-modified T regulatory cell characterised by genetic silencing of CIITA (HLA class II); and one, or two of the HLA class I gene loci HLA-A, HLA-B, and HLA-C; ii) particular embodiments provide a cell modified to have resistance to a particular immunosuppressive drug by gene silencing of the respective target gene; iii) the partial stealth concept combined with immunosuppression facilitates donor recipient matching using AI tools.

A platform for therapy provides: a chimeric molecule comprising one or more auto-antigens linked by a linker to a fluorescent protein; a chimeric molecule comprising three or more components linked by linker, the components comprising two or more auto-antigens of an autoimmune disease and one or more ablative molecule and / or toxin or one or more fluorescent molecules; a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to an autoimmune disease associated HLA class or HLA class II molecule and one or more ablative molecules and / or toxins or one or more fluorescent molecules; and a chimeric molecule comprising two or more components linked by linker, the components comprising an antibody or an antigen binding fragment thereof to a disease associated T-cell receptor and one or more fluorescent molecules or one or more ablative molecule and / or toxin

The present disclosure relates to methods of identifying MHC class II specific T cell receptors (TCRs). In certain aspects, the methods comprise contacting a T cell with a complex comprising (i) an MHC class II molecule having a higher affinity for CD4 than a naturally occurring MHC class II molecule, and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.

An isolated or purified T cell receptor (TCR) is disclosed that has antigen specificity for a mutant human RAS amino acid sequence in which glycine at position 12 is substituted with valine. The TCR can recognize G12V RAS presented by HLA-DR heterodimers. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods for detecting the presence of cancer in a mammal and methods for treating or preventing cancer in a mammal.

To provide methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells. [Solution] This disclosure provides a method for preparing personalized cancer vaccines. This disclosure also provides a method for training a machine learning HLA-peptide presentation predictive model. The methods and compositions described herein can be used in a wide range of applications. For example, the methods and compositions described herein can be used to identify immunogenic antigen peptides, and can also be used for the development of drugs such as personalized medicines, as well as for the isolation and characterization of antigen-specific T cells.

This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

To provide methods of identifying T cell receptors.SOLUTION: The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising (i) an MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.SELECTED DRAWING: None

To provide a further method for treating cancer.SOLUTION: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.SELECTED DRAWING: Figure 1

The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

The present invention discloses an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutant human RAS amino acid sequence in which glycine at position 12 is substituted with arginine. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, cell populations, and pharmaceutical compositions. Also disclosed are methods for detecting the presence of cancer in a mammal, and methods for treating or preventing cancer in a mammal.

The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

The present invention discloses an isolated or purified T cell receptor (TCR), wherein the TCR has antigen specificity for a mutant human RAS amino acid sequence in which glycine at position 12 is substituted with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal, and methods of treating or preventing cancer in a mammal.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof to provide immune compatible, allogeneic cell therapies. In the various aspects and embodiments, the cell populations and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the populations by gene editing, and methods for cell therapy involving cells or tissues derived from the cell populations (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

In various aspects and embodiments, the disclosure provides cell populations, or "banks" of cells thereof (e.g., cell collections), to provide immunocompatible, allogeneic cell therapies covering global, ethnical, and disease-specific populations. In various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA class I and HLA class II functions while promoting patient mating to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating a cell bank by gene editing, and methods for cell therapies involving cells or tissues derived from a cell bank, including but not limited to hematopoietic stem cells or "HSCs", progenitor cells, or progeny thereof.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specific populations. In the various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the cell banks by gene editing, and methods for cell therapy involving cells or tissues derived from the cell banks (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

The invention relates to the field of novel chimeric HLA class II molecules. The invention also relates to the field of novel chimeric HLA class II fusion polypeptides, nucleic acids, vectors, modified cells and compositions directed against celiac disease. Associated methods for use in treating and / or preventing celiac disease are also provided herein.

To provide polyomavirus epitopes useful for treating cancer or polyomavirus infection.SOLUTION: The present invention provides a peptide comprising a JC virus (JCV) epitope, the epitope being encoded by multiple specific amino acid sequences, the epitope being HLA class II restricted, one or more epitopes including one or more epitopes derived from a non-polyomavirus, and the one or more epitopes derived from a non-polyomavirus including one or more epitopes derived from an adenovirus, an Epstein-Barr virus, or a cytomegalovirus.SELECTED DRAWING: None

Disclosed are engineered cells and anti-CD19 CAR-expressing engineered immune cells having inactivated immune checkpoint genes and armoring modifications, including the engineered HLA Class I expression and inhibition of native HLA Class II expression, as well as therapeutic compositions including the cells, therapeutic methods including administration of the cells, and companion diagnostic methods for the therapeutic compositions.